Bambusa Therapeutics prices IPO at $16 per share on Nasdaq

Bambusa Therapeutics, Inc. (Nasdaq: BBTX), a clinical-stage biopharmaceutical company, priced its initial public offering of 10,555,555 shares of common stock at $16.00 per share, according to a press release.

The offering is expected to generate gross proceeds of approximately $168.9 million before underwriting discounts, commissions, and other expenses. Bambusa has also granted underwriters a 30-day option to purchase up to an additional 1,583,333 shares at the IPO price.

The company’s shares were expected to begin trading on the Nasdaq Global Select Market on Oct. 30, 2026, with the offering expected to close on Nov. 2, 2026, subject to customary closing conditions.

BofA Securities, Evercore ISI, UBS Investment Bank, and Cantor are acting as joint book-running managers for the offering.

Bambusa develops bispecific antibodies targeting immunology and inflammation. Its pipeline includes BBT001, targeting IL-4Rα and IL-31 for atopic dermatitis; BBT002, targeting IL-4Rα and IL-5 for Type 2 inflammatory disorders; and two preclinical programs, BBT003 and BBT004, focused on gastroenterology and autoimmune diseases.